Nanogel antigenic protein-delivery system for adjuvant-free intranasal vaccines

Nature Materials

Volumn 9, Issue 7, 2010, Pages 572-578

  Nochi, Tomonori ^a,e   Yuki, Yoshikazu ^a   Takahashi, Haruko ^b   Sawada, Shin Ichi ^b   Mejima, Mio ^a   Kohda, Tomoko ^c   Harada, Norihiro ^d   Kong, Il Gyu ^a   Sato, Ayuko ^a   Kataoka, Nobuhiro ^a   Tokuhara, Daisuke ^a   Kurokawa, Shiho ^a   Takahashi, Yuko ^a   Tsukada, Hideo ^d   Kozaki, Shunji ^c   Akiyoshi, Kazunari ^b   Kiyono, Hiroshi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^c Osaka Prefecture University   (Japan)

^d CENTRAL RESEARCH LABORATORY   (Japan)

^e UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGENS; DISEASES; HYDROGELS; NANOSTRUCTURED MATERIALS; PROTEINS; VACCINES;

ANTIBODY RESPONSE; BOTULINUM NEUROTOXINS; CHOLESTERYL GROUP-BEARING PULLULAN; CLOSTRIDIUM BOTULINUM; INFECTIOUS DISEASE; MUCOSAL IMMUNE RESPONSE; PROTEIN DELIVERY SYSTEMS; VACCINE DELIVERY SYSTEM;

IMMUNE SYSTEM;

BOTULINUM TOXIN A; NANOPARTICLE; VACCINE;

ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BRAIN; CHEMISTRY; CLOSTRIDIUM BOTULINUM; DRUG DELIVERY SYSTEM; FEMALE; GEL; IMMUNE SYSTEM; INTRANASAL DRUG ADMINISTRATION; MATERIALS TESTING; METABOLISM; METHODOLOGY; MOUSE; NANOTECHNOLOGY; OLFACTORY BULB;

ADMINISTRATION, INTRANASAL; ANIMALS; BOTULINUM TOXIN TYPE A; BRAIN; CLOSTRIDIUM BOTULINUM; DRUG DELIVERY SYSTEMS; FEMALE; GELS; IMMUNE SYSTEM; MATERIALS TESTING; MICE; MICE, INBRED BALB C; NANOPARTICLES; NANOTECHNOLOGY; OLFACTORY BULB; VACCINES;

EID: 77953900226     PISSN: 14761122     EISSN: 14764660     Source Type: Journal    
DOI: 10.1038/nmat2784     Document Type: Article

References (38)

1. Wagner, V., Dullaart, A., Bock, A. K. & Zweck, A. The emerging nanomedicine landscape. Nature Biotechnol. 24, 1211-1217 (2006).
2. Holmgren, J. & Czerkinsky, C. Mucosal immunity and vaccines. Nature Med. 11, S45-S53 (2005).
3. Varmus, H. et al. Public health. Grand challenges in global health. Science 302, 398-399 (2003).
4. Kiyono, H. & Fukuyama, S. NALT-versus Peyer's-patch-mediated mucosal immunity. Nature Rev. Immunol. 4, 699-710 (2004).
5. Belshe, R., Lee, M. S., Walker, R. E., Stoddard, J. & Mendelman, P. M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Exp. Rev. Vaccines 3, 643-654 (2004). (Pubitemid 39576751)
6. Lavelle, E. C. Generation of improved mucosal vaccines by induction of innate immunity. Cell. Mol. Life Sci. 62, 2750-2770 (2005).
7. Yuki, Y. & Kiyono, H. New generation of mucosal adjuvants for the induction of protective immunity. Rev. Med. Virol. 13, 293-310 (2003).
8. 2 cells in mucosa associated tissues. J. Exp. Med. 178, 1309-1320 (1993).
9. Takahashi, I. et al. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J. Infect. Dis. 173, 627-635 (1996).
10. Mutsch, M. et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. New Engl. J. Med. 350, 896-903 (2004).
11. van Ginkel, F. W., Jackson, R. J., Yuki, Y. & McGhee, J. R. Cutting edge: The mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. J. Immunol. 165, 4778-4782 (2000).
12. Reddy, S. T., Swartz, M. A. & Hubbell, J. A. Targeting dendritic cells with biomaterials: Developing the next generation of vaccines. Trends Immunol. 27, 573-579 (2006).
13. Peek,L. J., Middaugh,C. R. & Berkland, C. Nanotechnologyinvaccine delivery. Adv. Drug Deliv. Rev. 60, 915-928 (2008).
14. Sharma, S., Mukkur, T. K., Benson, H. A. & Chen, Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J. Pharm. Sci. 98, 812-843 (2009).
15. Oh, J. K., Drumright, R., Siegwart, D. J. & Matyjaszewski, K. The development of microgels/nanogels for drug delivery applications. Prog. Polym. Sci. 33, 448-477 (2008).
16. Reamdonck, K., Demeester, J. & Smedt, S. D. Advanced nanogel engineering for drug delivery. Soft Matter 5, 707-715 (2009).
17. Morimoto, N., Nomura, S., Miyazawa, N. & Akiyoshi, K. Nanogel engineered design for polymeric drug delivery. Polym. Drug Deliv. II, 88-101 (2006).
18. Akiyoshi, K., Deguchi, S., Moriguchi, N., Yamaguchi, S. & Sunamoto, J. Self-aggregates of hydrophobized polysaccharides in water. Macromolecules 26, 3062-3068 (1993).
19. Akiyoshi, K., Deguchi, S., Tajima, T., Nishikawa, T. & Sunamoto, J. Microscopic structure and thermoresponsiveness of a hydrogel nanoparticle by self-assembly of a hydrophobized polysaccharide. Macromolecules 30, 857-861 (1997).
20. Nomura, Y., Ikeda, M., Yamaguchi, N., Aoyama, Y. & Akiyoshi, K. Protein refolding assisted by self-assembled nanogels as novel artificial molecular chaperone. FEBS Lett. 553, 271-276 (2003).
21. Uenaka, A. et al. T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein. Cancer Immun. 7, 9 (2007).
22. Kageyama, S. et al. Humoral immune responses in patients vaccinated with 1-146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci. 99, 601-607 (2008).
23. Nishikawa, T., Akiyoshi, K. & Sunamoto, J. Macromolecular complexation between bovine serum albumin and the self-assembled hydrogel nanoparticle of hydrophobized polysaccharides. J. Am. Chem. Soc. 118, 6110-6115 (1996).
24. Akiyoshi, K., Sasaki, Y. & Sunamoto, J. Molecular chaperone-like activity of hydrogel nanoparticles of hydrophobized pullulan: Thermal stabilization with refolding of carbonic anhydrase B. Bioconjug. Chem. 10, 321-324 (1999).
25. Gu, X. G. et al. A novel hydrophobized polysaccharide/oncoprotein complex vaccine induces in vitro and in vivo cellular and humoral immune responses against HER2-expressing murine sarcomas. Cancer Res. 58, 3385-3390 (1998).
26. Ikuta, Y. et al. Presentation of a major histocompatibility complex class 1-binding peptide by monocyte-derived dendritic cells incorporating hydrophobized polysaccharide-truncated HER2 protein complex: Implications for a polyvalent immuno-cell therapy. Blood 99, 3717-3724 (2002).
27. Byrne, M. P., Smith, T. J., Montgomery, V. A. & Smith, L. A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 66, 4817-4822 (1998).
28. Ravichandran, E. et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun. 75, 3043-3054 (2007).
29. Ultrich, J., Cantrell, J., Gustafson, G., Rudbach, J. & Hiernant, J. The Adjuvant Activity of Monophosphoryl Lipid A 133-143 (CRC Press, 1991).
30. Fujihashi, K., Staats, H. F., Kozaki, S. & Pascual, D. W. Mucosal vaccine development for botulinum intoxication. Exp. Rev. Vaccines 6, 35-45 (2007).
31. Ayame, H., Morimoto, N. & Akiyoshi, K. Self-assembled cationic nanogels for intracellular protein delivery. Bioconjug. Chem. 19, 882-890 (2008).
32. Inoue, K. et al. Molecular composition of Clostridium botulinum type A progenitor toxins. Infect. Immun. 64, 1589-1594 (1996).
33. Fujinaga, Y., Matsumura, T., Jin, Y., Takegahara, Y. & Sugawara, Y. A novel function of botulinum toxin-associated proteins: HA proteins disrupt intestinal epithelial barrier to increase toxin absorption. Toxicon 54, 583-586 (2009).
34. Nochi, T. et al. A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses. J. Exp. Med. 204, 2789-2796 (2007).
35. Akiyoshi, K. et al. Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: Complexation and stabilization of insulin. J. Control. Release 54, 313-320 (1998).
36. Mizuta, T. et al. Performance evaluation of a high-sensitivity large-aperture small-animal PET scanner: ClairvivoPET. Ann. Nucl. Med. 22, 447-455 (2008).
37. Yuki, Y. et al. Production of a recombinant hybrid molecule of cholera toxin-B-subunit and proteolipid-protein-peptide for the treatment of experimental encephalomyelitis. Biotechnol. Bioeng. 74, 62-69 (2001).
38. Kobayashi, R. et al. A novel neurotoxoid vaccine prevents mucosal botulism. J. Immunol. 174, 2190-2195 (2005).